Benzinga | Sep 30, 2021 03:06PM EDT

Zogenix's Fintepla Shows Long-Term Seizure Frequency Reductions In Childhood Epilepsy

* Zogenix Inc (NASDAQ:ZGNX) has announced interim data from an ongoing 12-month Phase 3 open-label extension (OLE) study of Fintepla (fenfluramine) in Lennox-Gastaut syndrome (LGS).

* Data showed that fenfluramine oral solution led to a clinically meaningful and sustained reduction in drop seizures.

* A total of 247 patients entered the OLE study. During the treatment period, the median reduction in drop seizure frequency was 39.4% at 3 months and 51.8% for those patients assessed at months 10 to 12.

* Fintepla was generally well tolerated in the long-term trial with no observed valvular heart disease or pulmonary hypertension.

* One patient death occurred; the cause was reported as aspiration pneumonia and was considered unrelated to the study drug.

* Related Content: Zogenix's Fintepla Associated With Improvements in Seizure Control, Executive Functions In Childhood Epilepsy Disorder.

* Price Action: ZGNX stock is up 1.39% at $15.29 during the market session on the last check Thursday.